Endometrial Cancer Ec clinical trials

Explore recruiting endometrial cancer ec clinical trials.

Recruiting endometrial cancer ec studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Endometrial Cancer Ec trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator’s Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy

Poland, Denmark, Finland, Lithuania, France, Germany +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1/2 open-label, multicenter study of oral GSK5460025 alone or in combination with other anti-cancer agents in adult participants with Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) solid tumors.

Italy, Denmark, Spain, Sweden, Netherlands, France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Single cell characterization of persistent cells upon treatment with durvalumab (MEDI4736) with or without tremelimumab in MSS and MSI colorectal and endometrial tumors: the SERPENTINE clinical trial (Single cEll pRofiling PErsistaNce To ImmuNothErapy)

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase I-II Study to Assess the Safety, Tolerability and Efficacy of Lurbinectedin and Dostarlimab in Advanced/Recurrent Endometrial Cancer Patients with Disease Progression after Prior Therapy with Platinum-based Chemotherapy. LiDer trial

Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) in Subjects With Selected Tumor Types

France, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

Denmark

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Endometrial Cancer Ec trials by city

Endometrial Cancer Ec in Toronto Endometrial Cancer Ec in Vancouver Endometrial Cancer Ec in Montreal Endometrial Cancer Ec in Calgary Endometrial Cancer Ec in Edmonton Endometrial Cancer Ec in Ottawa Endometrial Cancer Ec in Winnipeg Endometrial Cancer Ec in Quebec City Endometrial Cancer Ec in Hamilton Endometrial Cancer Ec in Kitchener Endometrial Cancer Ec in London Endometrial Cancer Ec in Halifax Endometrial Cancer Ec in New York Endometrial Cancer Ec in Los Angeles Endometrial Cancer Ec in Chicago Endometrial Cancer Ec in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease